Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
August 01 2023 - 08:45AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK),
a biopharmaceutical company working to achieve FDA
approval for the first ophthalmic formulation of bevacizumab for
the treatment of wet AMD, today announced that Russell Trenary,
President and Chief Executive Officer of Outlook Therapeutics will
participate in a fireside chat at the BTIG Virtual Biotechnology
Conference 2023 on Monday, August 7, 2023 at 1:00 PM ET.
In addition to the fireside chat, management
will be available to participate in virtual one-on-one meetings
with qualified members of the investor community who are registered
to attend the conference.A live video webcast of the fireside chat
will be accessible on the Events page in the Investors section of
the Company’s website (outlooktherapeutics.com). The webcast replay
will be archived for 90 days following the event.About
Outlook Therapeutics, Inc.Outlook Therapeutics is a
biopharmaceutical company working to achieve FDA approval for the
launch of ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first
FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, including wet AMD, DME and BRVO. The FDA
accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat
wet AMD with a PDUFA goal date of August 29, 2023. The submission
is supported by Outlook Therapeutics’ wet AMD clinical program,
which consists of three clinical trials: NORSE ONE, NORSE TWO, and
NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan, and other markets. As part of the Company’s
multi-year commercial planning process, and in anticipation of
potential FDA approval in August 2023, Outlook Therapeutics and
AmerisourceBergen have entered into a strategic commercialization
agreement to expand the Company’s reach for connecting to retina
specialists and their patients. AmerisourceBergen will provide
third-party logistics (3PL) services and distribution, as well as
pharmacovigilance services and other services in the United States.
For more information, please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Nov 2023 to Dec 2023
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2022 to Dec 2023